Skip to main content
Premium Trial:

Request an Annual Quote

New Products: InVitae's Hereditary Pancreatic Cancer Test; Enzymatics' Archer FusionPlex; More

Premium

InVitae has launched a hereditary pancreatic cancer panel that covers 17 genes related to pancreatic cancer and the option of adding two genes related to hereditary pancreatitis. The test costs $1,500 in the US and has a turnaround time of three weeks.


Enzymatics has updated its Archer FusionPlex ALK, RET, ROS1 Panel to now include select point mutations in ALK and RET that confer resistance to crizotinib.


MolecularMD, in collaboration with OncoMed, is developing a Notch1 next-generation sequencing-based test. The Notch1 NGS Assay is being developed as a companion diagnostic to identify patients whose cancer may be more likely to benefit from OncoMed's anti-Notch1 antibody, OMP-52M51.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.